| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
1 Department of Otolaryngology-Head and Neck Surgery, The Johns Hopkins School of Medicine, Baltimore, Maryland, and 2 Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland
Aberrant promoter hypermethylation of several known or putative tumor suppressor genes occurs frequently during the pathogenesis of human cancers and is a promising marker for cancer detection. We investigated the feasibility of detecting aberrant DNA methylation in the urine and serum samples of renal cancer patients. We examined the tumor and the matched urine and serum DNA for aberrant methylation of nine gene promoters (CDH1, APC, MGMT, RASSF1A, GSTP1, p16, RAR-ß2, and ARF) from 17 patients with primary kidney cancer by quantitative fluorogenic real-time PCR. An additional 9 urine samples (total, 26) and 1 serum sample (total, 18) also were tested from renal cancer patients. Urine from 91 patients without genitourinary cancer and serum from 30 age-matched noncancer individuals were used as controls. Promoter hypermethylation of at least two of the genes studied was detected in 16 (94%) of 17 primary tumors. Aberrant methylation in urine and serum DNA generally was accompanied by methylation in the matched tumor samples. Urine samples from 91 control subjects without evidence of genitourinary cancer revealed no methylation of the MGMT, GSTP1, p16, and ARF genes, whereas methylation of RAR-ß2, RASSF1A, CDH1, APC, and TIMP3 was detected at low levels in a few control subjects. Overall, 23 (88%) of 26 urine samples and 12 (67%) of 18 serum samples from cancer patients were methylation positive for at least one of the genes tested. By combination of urine or serum analysis of renal cancer patients, hypermethylation was detected in 16 of 17 patients (94% sensitivity) with high specificity. Our findings suggest that promoter hypermethylation in urine or serum can be detected in the majority of renal cancer patients. This noninvasive high-throughput approach needs to be evaluated in large studies to assess its value in the early detection and surveillance of renal cancer.
This article has been cited by other articles:
|
|
 |
|
  M. Brait, J. G. Ford, S. Papaiahgari, M. A. Garza, J. I. Lee, M. Loyo, L. Maldonado, S. Begum, L. McCaffrey, M. Howerton, et al. Association between Lifestyle Factors and CpG Island Methylation in a Cancer-Free Population Cancer Epidemiol. Biomarkers Prev., November 1, 2009; 18(11): 2984 - 2991. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K.C. A. Chan, S. F. Leung, S. W. Yeung, A. T.C. Chan, and Y.M. D. Lo Quantitative Analysis of the Transrenal Excretion of Circulating EBV DNA in Nasopharyngeal Carcinoma Patients Clin. Cancer Res., August 1, 2008; 14(15): 4809 - 4813. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. L. Carvalho, C. Jeronimo, M. M. Kim, R. Henrique, Z. Zhang, M. O. Hoque, S. Chang, M. Brait, C. S. Nayak, W.-W. Jiang, et al. Evaluation of Promoter Hypermethylation Detection in Body Fluids as a Screening/Diagnosis Tool for Head and Neck Squamous Cell Carcinoma Clin. Cancer Res., January 1, 2008; 14(1): 97 - 107. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Zou, J. J. Harrington, A. M. Shire, R. L. Rego, L. Wang, M. E. Campbell, A. L. Oberg, and D. A. Ahlquist Highly Methylated Genes in Colorectal Neoplasia: Implications for Screening Cancer Epidemiol. Biomarkers Prev., December 1, 2007; 16(12): 2686 - 2696. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Yue, S. Dacic, Q. Sun, R. Landreneau, M. Guo, W. Zhou, J. M. Siegfried, J. Yu, and L. Zhang Frequent Inactivation of RAMP2, EFEMP1 and Dutt1 in Lung Cancer by Promoter Hypermethylation Clin. Cancer Res., August 1, 2007; 13(15): 4336 - 4344. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. Feng, S. E. Hawes, J. E. Stern, A. Dem, P. S. Sow, B. Dembele, P. Toure, P. Sova, P. W. Laird, and N. B. Kiviat Promoter Hypermethylation of Tumor Suppressor Genes in Urine from Patients with Cervical Neoplasia Cancer Epidemiol. Biomarkers Prev., June 1, 2007; 16(6): 1178 - 1184. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Roupret, V. Hupertan, D. R. Yates, J. W.F. Catto, I. Rehman, M. Meuth, S. Ricci, R. Lacave, G. Cancel-Tassin, A. de la Taille, et al. Molecular Detection of Localized Prostate Cancer Using Quantitative Methylation-Specific PCR on Urinary Cells Obtained Following Prostate Massage Clin. Cancer Res., March 15, 2007; 13(6): 1720 - 1725. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Gu, D. Berman, C. Lu, I. I. Wistuba, J. A. Roth, M. Frazier, M. R. Spitz, and X. Wu Aberrant Promoter Methylation Profile and Association with Survival in Patients with Non-Small Cell Lung Cancer Clin. Cancer Res., December 15, 2006; 12(24): 7329 - 7338. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Urakami, H. Shiina, H. Enokida, H. Hirata, K. Kawamoto, T. Kawakami, N. Kikuno, Y. Tanaka, S. Majid, M. Nakagawa, et al. Wnt Antagonist Family Genes as Biomarkers for Diagnosis, Staging, and Prognosis of Renal Cell Carcinoma Using Tumor and Serum DNA Clin. Cancer Res., December 1, 2006; 12(23): 6989 - 6997. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. O. Hoque, Q. Feng, P. Toure, A. Dem, C. W. Critchlow, S. E. Hawes, T. Wood, C. Jeronimo, E. Rosenbaum, J. Stern, et al. Detection of Aberrant Methylation of Four Genes in Plasma DNA for the Detection of Breast Cancer J. Clin. Oncol., September 10, 2006; 24(26): 4262 - 4269. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Ibanez de Caceres, E. Dulaimi, A. M. Hoffman, T. Al-Saleem, R. G. Uzzo, and P. Cairns Identification of novel target genes by an epigenetic reactivation screen of renal cancer. Cancer Res., May 15, 2006; 66(10): 5021 - 5028. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Kim, K. Yamashita, J. H. Baek, H. L. Park, A. L. Carvalho, M. Osada, M. O. Hoque, S. Upadhyay, M. Mori, C. Moon, et al. N-methyl-D-aspartate receptor type 2B is epigenetically inactivated and exhibits tumor-suppressive activity in human esophageal cancer. Cancer Res., April 1, 2006; 66(7): 3409 - 3418. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Yamashita, H. L. Park, M. S. Kim, M. Osada, Y. Tokumaru, H. Inoue, M. Mori, and D. Sidransky PGP9.5 Methylation in Diffuse-Type Gastric Cancer. Cancer Res., April 1, 2006; 66(7): 3921 - 3927. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-W. Cheng, C. Shawber, D. Notterman, P. Paty, and F. Barany Multiplexed profiling of candidate genes for CpG island methylation status using a flexible PCR/LDR/Universal Array assay Genome Res., February 1, 2006; 16(2): 282 - 289. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Hu, M. Ewertz, R. P. Tufano, M. Brait, A. L. Carvalho, D. Liu, A. P. Tufaro, S. Basaria, D. S. Cooper, D. Sidransky, et al. Detection of Serum Deoxyribonucleic Acid Methylation Markers: A Novel Diagnostic Tool for Thyroid Cancer J. Clin. Endocrinol. Metab., January 1, 2006; 91(1): 98 - 104. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Mori, S. J. O'Day, N. Umetani, S. R. Martinez, M. Kitago, K. Koyanagi, C. Kuo, T.-L. Takeshima, R. Milford, H.-J. Wang, et al. Predictive Utility of Circulating Methylated DNA in Serum of Melanoma Patients Receiving Biochemotherapy J. Clin. Oncol., December 20, 2005; 23(36): 9351 - 9358. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Murray, M. Mavrakis, N. J. McDonald, M. Yilla, J. Sheng, W. J. Bellini, L. Zhao, J. M. Le Doux, M. W. Shaw, C.-C. Luo, et al. Rab9 GTPase Is Required for Replication of Human Immunodeficiency Virus Type 1, Filoviruses, and Measles Virus J. Virol., September 15, 2005; 79(18): 11742 - 11751. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. O. Hoque, E. Rosenbaum, W. H. Westra, M. Xing, P. Ladenson, M. A. Zeiger, D. Sidransky, and C. B. Umbricht Quantitative Assessment of Promoter Methylation Profiles in Thyroid Neoplasms J. Clin. Endocrinol. Metab., July 1, 2005; 90(7): 4011 - 4018. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Lodygin, A. Epanchintsev, A. Menssen, J. Diebold, and H. Hermeking Functional Epigenomics Identifies Genes Frequently Silenced in Prostate Cancer Cancer Res., May 15, 2005; 65(10): 4218 - 4227. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Agathanggelou, W. N. Cooper, and F. Latif Role of the Ras-Association Domain Family 1 Tumor Suppressor Gene in Human Cancers Cancer Res., May 1, 2005; 65(9): 3497 - 3508. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X.-f. Wang, D. Z. Qian, M. Ren, Y. Kato, Y. Wei, L. Zhang, Z. Fansler, D. Clark, O. Nakanishi, and R. Pili Epigenetic Modulation of Retinoic Acid Receptor {beta}2 by the Histone Deacetylase Inhibitor MS-275 in Human Renal Cell Carcinoma Clin. Cancer Res., May 1, 2005; 11(9): 3535 - 3542. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. W. Laird Cancer epigenetics Hum. Mol. Genet., April 15, 2005; 14(suppl_1): R65 - R76. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
